Sodium valproate (Epilim) in epilepsy: a trial

Area of Science:

• Neurology
• Pharmacology

Background:

• Epilepsy is a neurological disorder characterized by recurrent seizures.
• Sodium valproate is a commonly used antiepileptic drug.

Purpose of the Study:

• To evaluate the efficacy and tolerability of sodium valproate in patients with various epilepsy types.
• To identify patient subgroups that may benefit most from sodium valproate treatment.

Main Methods:

• A cohort of thirty-five patients with different epilepsy types received sodium valproate.
• Treatment outcomes, including seizure control, side effects, and patient-reported well-being, were assessed.
• Plasma valproate levels were measured and correlated with treatment response.

Main Results:

• Fifteen patients achieved complete seizure control with sodium valproate alone.
• Twelve patients showed improvement, while eight did not respond.
• Excellent outcomes were more frequent in patients with petit mal epilepsy and those previously experiencing side effects from other drugs.
• Only three patients were intolerant to sodium valproate, with most experiencing few side effects.
• Several patients reported feeling better on sodium valproate compared to their prior medications.
• A twice-daily dosage regimen was found to be satisfactory.
• Plasma valproate levels ranged from 0.21 to 1.2 mmol/l but did not correlate with response or side effects.

Conclusions:

• Sodium valproate is an effective and generally well-tolerated antiepileptic drug for various epilepsy types.
• Patients with petit mal epilepsy and those with a history of side effects from other antiepileptic drugs may particularly benefit.
• The studied dosage regimen and plasma levels did not predict treatment success or adverse events.